OVERVIEW

Key Insights: Reaching Beyond Anti-TNFs in Moderate to Severe Ulcerative Colitis is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Dec 21, 2018 - Dec 21, 2019.

Accreditation:
CME
Physicians
Imedex designates this live educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™.
Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 credit.
PAs should only claim credit commensurate with the extent of their participation.

CNE
This continuing nursing education activity awards 0.5 contact hour.

CPE
This knowledge-based activity (JA0006201-9999-18-245-H01-P) is approved for 0.5 contact hour (0.005 CEUs) of continuing pharmacy education.

Target Audience:
This activity is intended for IBD specialists, gastroenterologists, nurses, nurse practitioners, and other healthcare professionals (internists, primary care physicians, physician assistants, pharmacists, etc) involved and/or interested in the therapeutic management of patients with IBD.

Overview:
Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), causes inflammation of large intestine resulting in the formation of ulcers. An overactive immune system is thought to be one of the causes of UC. Depending on the severity of symptoms, a wide range of drugs including, antibiotics, corticosteroids, immunomodulators, and biologics are prescribed to treat UC. Janus kinase (JAK) molecules and immunologic pathways have been shown to play a major role in the inflammation of mucosal lining, leading to investigation of JAK inhibitors to treat UC.

In this Key Insights™ activity, Dr. Millie D. Long discusses the key take-home messages from the Reaching Beyond Anti-TNFs in Moderate to Severe UC symposium, held on December 13, 2018 during the 2018 Advances in Inflammatory Bowel Diseases conference in Orlando, Florida.

Objectives:
Upon successful completion of this educational activity, participants should be better able to:
• Discuss the benefits of a treat-to-target versus step-care approach to UC treatment with regards to disease progression and clinical outcomes
• Differentiate among newer and emerging classes of targeted therapies for UC in terms of their mechanisms of action and therapeutic potential
• Evaluate the pivotal clinical trial data surrounding the efficacy and safety of newer and emerging targeted therapies for UC
• Integrate the latest clinical data, FDA approvals, and guideline recommendations into individualized UC management plans